medRxiv preprint doi: https://doi.org/10.1101/2020.07.17.20155937; this version posted October 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

1 Antibody responses to SARS-CoV-2 train machine learning to assign likelihood of past 2 infection during virus emergence in Sweden

3

Xaquín Castro Dopico^{1#}, Leo Hanke^{1°}, Daniel J. Sheward^{1°}, Sandra Muschiol², Soo Aleman³,
Murray Christian¹, Nastasiya F. Grinberg⁴, Monika Adori¹, Laura Perez Vidakovics¹, Changll
Kim¹, Sharesta Khoenkhoen¹, Pradeepa Pushparaj¹, Ainhoa Moliner Morro¹, Marco
Mandolesi¹, Marcus Ahl³, Mattias Forsell⁵, Jonathan Coquet¹, Martin Corcoran¹, Joanna
Rorbach^{6,7}, Joakim Dillner⁸, Gordana Bogdanovic², Gerald McInerney¹, Tobias Allander^{1,2},
Chris Wallace^{4,9*}, Ben Murrell^{1*}, Jan Albert^{1,2*}, Gunilla B. Karlsson Hedestam^{1#}

10

11 Affiliations:

- ¹Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
- 13 ²Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
- ³ Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden
- 15 ⁴Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre,
- 16 Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0AW
- ⁵Department of Clinical Microbiology, Umeå Universitet, Umeå 901 85, Sweden
- 18 ⁶Department of Molecular Biochemistry & Biophysics, Karolinska Institutet, Stockholm 171 77, Sweden
- ⁷Max Planck Institute-Biology of Ageing, Karolinska Institutet Laboratory, Stockholm 171 77, Sweden
- 20 ⁸Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge 141 52, Sweden
- ⁹MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge CB2 OSR, United Kingdom

22

- 23 °*Equal contribution
- 24 #Correspondence
- 25
- 26
- 27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Abstract

29

30 Serology is critical for understanding pathogen-specific immune responses, but is fraught with difficulty, not least because the strength of antibody (Ab) response varies greatly between 31 individuals and mild infections generally generate lower Ab titers^{1–3}. We used robust IgM, IgG 32 and IgA Ab tests to evaluate anti-SARS-CoV-2 responses in individuals PCR+ for virus RNA 33 34 (n=105) representing different categories of disease severity, including mild cases. All PCR+ 35 individuals in the study became IgG-positive against pre-fusion trimers of the virus spike (S) 36 glycoprotein, but titers varied greatly. Elevated IgA, IL-6 and neutralizing responses were 37 present in intensive care patients. Additionally, blood donors and pregnant women (n=2,900) 38 sampled throughout the first wave of the pandemic in Stockholm, Sweden, further 39 demonstrated that anti-S IgG titers differed several orders of magnitude between individuals, with an increase of low titer values present in the population at later time points^{4,5}. To 40 41 improve upon current methods to identify low titers and extend the utility of individual measures^{6,7}, we used our PCR+ individual data to train machine learning algorithms to assign 42 likelihood of past infection. Using these tools that assigned probability to individual responses 43 44 against S and the receptor binding domain (RBD), we report SARS-CoV-2-specific IgG in 13.7% 45 of healthy donors five months after the peak of spring COVID-19 deaths, when mortality and ICU occupancy in the country due to the virus were at low levels. These data further our 46 47 understanding of antibody responses to the virus and provide solutions to problems in serology data analysis. 48

49

50 Significance statement:

51 Antibody testing provides critical clinical and epidemiological information during an emerging 52 disease pandemic. We developed robust SARS-CoV-2 IgM, IgG and IgA antibody tests and 53 profiled COVID-19 patients and exposed individuals throughout the outbreak in Stockholm, Sweden, where full societal lockdown was not employed. As well as elucidating several 54 55 disease immunophenotypes, our data highlight the challenge of identifying low IgG titer 56 individuals, who comprise a significant proportion of the population following mild/asymptomatic infection, especially as antibody titers wane following peak responses. To 57 58 provide a solution to this, we used SARS-CoV-2 PCR+ individual data to develop machine 59 learning approaches that assigned *likelihood of past infection* to blood donors and pregnant 60 women, improving the accuracy and utility of individual and population-level Ab measures. 61

62

medRxiv preprint doi: https://doi.org/10.1101/2020.07.17.20155937; this version posted October 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

63 Introduction

64 Characterization of the humoral response to nascent SARS-CoV-2 outbreaks is central to 65 optimizing approaches to the pandemic and further our understanding of human 66 immunology^{8,9}. Here, we followed the first wave of the pandemic in Stockholm, Sweden, 67 characterizing Ab responses in severely ill COVID-19 patients and exposed healthy individuals. 68

69 Despite the plethora of Ab testing and phenotyping for SARS-CoV-2¹⁰⁻¹⁷, consensus on several key issues remains outstanding. For instance, the majority of data are derived from 70 71 commercial, mass-produced kits utilizing spike derivatives (e.g. S1 or S2 domains) or the nucleocapsid to detect pathogen-specific antibodies^{10,18,19}. Many of these assays suffer from 72 epitope loss/modification²⁰, cross-reactivity^{10,21} and suboptimal sensitivity²²⁻²⁵. Here, we 73 developed highly sensitive and specific ELISA protocols based on in-house native-like pre-74 fusion-stabilized spike (S) trimers²⁶ and the smaller ACE-2 receptor-binding domain (RBD), 75 76 and used them in tandem to evaluate anti-viral Ab responses. As S and the RBD are required 77 for ACE-2-mediated cell entry, we also examined virus neutralisation capacity and isotype 78 levels alongside a descriptive set of clinical features.

79

Aside from the target antigen, a major consideration for Ab testing concerns setting the assay cut-off for positivity. Commonly, 3 or 6 standard deviations (SD) from the mean of negative controls is used²⁷⁻²⁹, which is highly dependent on a representative set of negative control sera - significantly affecting seroprevalence estimates and individual clinical management³⁰. It is important to note that humoral responses within the population are not so much *positive* or *negative*, but rather represent a wide spectrum², highlighting the need for more

quantitative tools to examine low titer individuals. To obtain accurate seroprevalence estimates in key community groups, we strictly controlled our assay with a large number of historical controls (*n*=595, repeatedly analyzed alongside test samples) and used tandem anti-S and RBD responses from SARS-CoV-2 PCR+ individuals to train machine learning (ML)

- 90 algorithms on ELISA measurements.
- 91

Developing these approaches, that assigned likelihood of past infection to each data point 92 93 (values and code openly available), we sampled 100 blood donors and 100 pregnant women 94 per week throughout the outbreak in Stockholm. Both groups are a good proxy for population 95 health. Furthermore, blood donors serve as an important clinical resource (including for 96 COVID-19 plasma therapy), while pregnant women require close clinical monitoring with 97 respect to fetal-maternal health and are known to employ poorly characterized immunological mechanisms impacting infectious pathology^{31–33}. The study was terminated 98 99 when new cases, mortality and ICU occupancy were at low levels. As Sweden did not impose 100 a strict lockdown in response to the pandemic, these data provide a contrast to comparable 101 settings where social lockdown was not imposed.

102

103 Results

104

105 Study samples are detailed in Table 1.

106

Antibody test development 107

We developed ELISA protocols to profile IgM, IgG and IgA specific for a stabilized spike (S) 108 109 glycoprotein trimer²⁶, the RBD, and the internal viral nucleocapsid (N). The two S antigens were produced in mammalian cells (Fig. S1A) and the trimer conformation was confirmed in 110 each batch by cryo-EM³⁴. A representative subset of study samples (n = 230, Fig S1) was used 111 112 for assay development (Fig. S1B). No IgG reactivity was recorded amongst the negative control samples during test development, although two individuals who were PCR-positive 113 114 for endemic coronavirus-positive (ECV+) displayed reproducible IgM reactivity to SARS-CoV-2 N and S, and two 2019 blood donors had low anti-S IgM reactivity (Fig. S1C). Thus, further 115 investigation is required to establish the contribution of cross-reactive memory and germline 116 immunoglobulin alleles to SARS-CoV-2 responses³⁵. We did not observe reproducible IgG 117 reactivity to S or RBD across all 595 historical controls in the study. 118

119

Our assay revealed a greater than 10,000-fold difference in anti-viral IgG titers between Ab-120 positive individuals when examining serially diluted sera. In SARS-CoV-2 PCR+ individuals, 121 122 anti-viral IgG titers were comparable for S (EC₅₀=3,064; 95% CI [1,197 - 3,626]) and N (EC₅₀=2,945; 95% CI [543 - 3,936]) and lower for RBD [EC₅₀=1,751; 95% CI 966 - 1,595]. A 123 124 subset (ca. 10%) of the SARS CoV-2-confirmed individuals in test development did not have detectable IgG responses against N (Fig. S1D), as previously reported¹⁰. Therefore, we did not 125 126 explore responses to N further.

127

128 Elevated anti-viral Ab titers are associated with increased disease severity

We next screened all SARS-CoV-2 PCR+ individuals collected for the study (n=105) and 129 130 detected potent IgG responses against S in all participants, and against RBD in 97% of persons 131 (Fig. 1A and S2A). In healthy blood donors and pregnant women, titers varied greatly but were 132 generally lower (Fig. 1A and S2A). In PCR+ patients, IgM and IgA responses against S and RBD 133 were generally weaker and more variable between individuals than the IgG response (Fig. 1B 134 and S2B). Therefore, we sought to investigate whether isotype titers segregated with clinical 135 features.

136

137 To achieve this, SARS-CoV-2 PCR+ individuals (*n*=105) were grouped with regards to their disease severity: Category 1 – non-hospitalized (mild and asymptomatic infections); Category 138 139 2 – hospitalized; Category 3 – intensive care (on mechanical ventilation) (Table 1). In all PCR+ 140 individuals, anti-S and anti-RBD responses were highly correlated (Fig. S2C) and multivariate analyses revealed that increased anti-viral IgM, IgG and IgA were positively correlated with 141 142 disease severity (Supp. Table 1), in line with the lower titers observed in blood donors and 143 pregnant women, who did not have signs or symptoms of COVID-19 when they were sampled.

Severe disease was most associated with virus-specific IgA, suggestive of mucosal disease³⁶, 144 as well as elevated serum IL-6 (Fig. 1C and S2D), a cytokine that feeds Ab production³⁷⁻⁴⁰. IL-145 6 is dysregulated in several common non-communicable diseases⁴¹⁻⁴³ and during acute 146 respiratory distress syndrome⁴⁴, risk factors for COVID-19-associated mortality^{45,46}. 147 Interestingly, we observed a lack of association between IL-6 and IgM levels, supporting that 148 149 levels of the cytokine and IgA mark a protracted, severe clinical course of COVID-19. IgA anti-150 RBD responses were lower in non-hospitalized and hospitalized females as compared to 151 males, trending similarly for S (Fig. S3A) and in line with females developing less severe disease⁴⁷. 152

153

154 In our study, PCR+ individual anti-viral IgG levels were maintained two months post-disease onset/positive PCR test, while IgM and IgA decreased, in agreement with their circulating $t_{1/2}$ 155 and viral clearance (Fig. S3B). In longitudinal patient samples (sequential serum sampling of 156 157 10 PCR+ individuals in the study) where we observed seroconversion, IgM, IgG and IgA peaked 158 with similar kinetics when all three isotypes developed, although IgA was not always 159 generated in Category 1 and 2 individuals (Fig 1D). Overall, disease severity showed the most consistent relationship with any measure and was the primary predictor of Ab levels (Fig. S3C 160 161 and D).

162

163 We next characterized the virus neutralizing Ab response, a key parameter for understanding the potential for protective humoral immune responses and the selection of plasma therapy 164 donors. Benefitting from a robust in vitro pseudotype virus neutralization assay⁴⁸, we 165 measured serum inhibition of viral cell entry and detected neutralizing antibodies in the 166 serum of all SARS-CoV-2 PCR+ individuals (n=48), and in all except two healthy Ab-positive 167 donors screened (n=56). Neutralizing responses were not seen in samples before 168 seroconversion (Fig. 1D) or negative controls. A large range of neutralizing ID₅₀ titers was 169 170 apparent, with binding and neutralizing Ab levels being highly correlated (Fig. S3D). The 171 strongest neutralizing responses were observed in samples from patients on mechanical 172 ventilation in intensive care (Category 3, g.mean ID₅₀=5,058; 95% CI [2,422 - 10,564]), in-173 keeping with their elevated Ab response (Fig 1E). Sera from healthy blood donors and 174 pregnant women also displayed neutralizing responses, but consistent with the binding data 175 were less potent than those observed in individuals with severe disease (ID_{50} =600; 95% CI 176 [357 – 1,010] and ID₅₀=350; 95% CI [228 - 538], respectively, Fig. 1F). Across the two antigens 177 and three isotypes, anti-RBD IgG levels were most strongly correlated with neutralization.

178

179 Probabilistic seroprevalence estimates in blood donors and pregnant women

180 As Stockholm is a busy urban area and Sweden did not impose strict lockdown in response to 181 SARS-CoV-2 emergence, we sought to better understand the frequency and nature of antiviral responses in healthy blood donors and pregnant women sampled throughout the first 182 outbreak (March 30 - August 23rd 2020) (Fig. 2A). However, critical to accurate individual 183 184 measures and seroprevalence estimates is the decision about whether a sample is defined as

185 positive or not. For example, current clinically approved tests use a ratio between a 186 "representative" positive and negative serum calibrator to determine positivity, although we 187 show here that these are highly variable.

188

To improve our understanding of the assay boundary, we repeatedly analyzed a large number 189 190 of historical (SARS-CoV-2-negative) controls (blood donors from the spring of 2019, *n*=595) 191 alongside test samples throughout the study. We considered the spread of negative values 192 critical, since the use of a small and unrepresentative set of controls can lead to an incorrectly 193 set threshold and errors in the seroprevalence measurement. This is illustrated by the random 194 sub-sampling of non-overlapping groups of negative controls, resulting in a 40% difference in 195 the seroprevalence estimate (Fig. S4A). Seroprevalence in the healthy cohorts according to conventional 3 and 6 SD cut-offs are shown in Fig. 2C. 196

197

205

198 The fact that many healthy donor test samples had optical densities between the 3 and 6 SD 199 cut-offs for both or a single antigen (Fig. 2B and C), highlights the problem of assigning case 200 to low responder values. Therefore, to exploit individual titers and improve our statistical 201 estimates, we used the data from PCR+ individuals (Fig. 1) and our negative controls (Fig. S4B) 202 to train machine learning (ML) algorithms to assign likelihood of past infection. A small cohort 203 of seropositive individuals among Karolinska University Hospital staff (n=33) provided 204 additional low titer training values four months post SARS-CoV-2+ PCR (Fig. S4C).

206 After comparing different methods for this purpose (Materials & Methods), we found that 207 logistic regression (LOG) achieved the highest sensitivity, while linear discriminant analysis 208 (LDA) showed the best specificity. LOG and LDA both model log odds of a sample being case 209 as a linear equation with a resulting linear decision boundary, but differ in how the 210 coefficients for the linear models are estimated from the data. When applied to the Ab 211 response data, the output of LOG and LDA is the probability of each new sample being case. 212 Therefore, we generated an equal-weighted ensemble learner (ENS) from the output of LOG 213 and LDA that maximized sensitivity, specificity and consistency across different cross-214 validation strategies (Fig. 2D and S4D). While weekly rates varied (S Table 2), the ENS learner 215 identified 13.7% seroprevalence in healthy blood donors and pregnant women at the last 216 sampling week (Supp. Table 2). Importantly, ENS identified 155 (5.3%) blood donor and 217 pregnant women measures to be associated with some degree of uncertainty, encouraging 218 follow-up investigation in given cases (Fig. 2E and S4E).

219

220 Finally, to model population changes in seroprevalence over time, we developed and 221 validated a cut-off-independent Bayesian ML framework able to share information between sampling weeks⁴⁹ (Fig. 2F and Materials & Methods). Using this model on the combined BD 222 223 and PW data, we found an almost linear increase in seroprevalence since the start of the 224 pandemic (Fig. 2E), consistent with continued virus spread in the Stockholm population during 225 the study period. The results mirrored the results obtained using ENS, yielding a

- 226 seroprevalence of 13.2% (95% Bayesian CI [10.1-16.8]) at the end of the study period (Supp.
- 227 Table 3). We propose that these tools and related approaches be used to facilitate future
- antibody measures and better characterize Ab test uncertainty at individual and population 228
- 229 levels.

230

231 Discussion

232

233 Serology remains the gold standard for estimating previous exposure to pathogens and 234 benefits from a large historical literature. Although the concept of herd immunity is based upon the study of antibodies, worryingly, there is no standardization for the many SARS-CoV-235 236 2 Ab tests currently available. Globally, hospital staff and health authorities are struggling 237 with test choices, negatively impacting individual outcomes and efforts to contain the 238 pandemic.

239

240 Benefitting from a robust antibody test developed alongside a diagnostic clinical laboratory 241 responsible for monitoring sero-reactivity during the pandemic, we profiled SARS-CoV-2 Ab 242 responses in three cohorts of clinical interest. COVID-19 patients receiving intensive care showed the highest anti-viral Ab titers, developing augmented serum IgA and IL-6 with 243 244 worsening disease. Isotype-level measures may assist COVID-19 clinical management and determine, for example, whether all critically ill patients develop class-switched mucosal 245 responses to SARS-CoV-2, potentially informing lung therapeutic delivery^{50,51}. Our 246 neutralization data showed that nearly all SARS-CoV-2 PCR+ individuals and healthy donors 247 248 who seroconvert, develop neutralizing Ab capable of preventing S-mediated cell entry in vitro.

249

250 Outside of the severe disease setting, it is critical to accurately determine who and how many 251 people have seroconverted. This is complicated by low titer values, which in some cases - and 252 increasingly with time since exposure - overlap outlier values among negative control 253 samples. Test samples with true low anti-viral titers will, therefore, fall into this range of weak 254 responders as the B lymphocyte response contracts following viral clearance, highlighting the 255 need to better understand the assay boundary in multiple dimensions. As future tests begin 256 to survey individual Ab responses to a multitude of antigens in parallel, the ML approaches 257 presented here will enable the identification of disease sub-types and facilitate longitudinal 258 measures.

259

260 We applied these tools to blood donors and pregnant women, two good sentinels for 261 population health, although they are not enriched for groups with high risk for SARS-CoV-2 262 infection, such as healthcare workers and public transportation employees, where seroprevalence may be higher. Blood donors are generally working age, active and mobile 263 264 members of society with a good understanding of health, and pregnant women in Sweden will have been advised to take precautions against infectious diseases through their 265 266 practitioners. Interestingly, in our study, both groups showed a similar seroprevalence during the time period analyzed. Tracking these cohorts over time, we modelled seroprevalence 267 268 changes at the population level. We found the steep climb in Ab positivity at the start of the pandemic (as the virus emerged) to increase at a slower rate during subsequent weeks, 269 270 reaching nearly 14% by five months from the peak of spring 2020 COVID-19 deaths in the 271 country. These data indicate that serological herd immunity to the initial outbreak was not

- achieved in these cohorts. We terminated the study in line with the decreasing caseload and 272
- number of fatalities in Sweden⁵², despite on-going virus spread in the Stockholm population. 273 274
- Given the uniqueness of the public health response to the pandemic in the country⁵³, these 275
- 276 data may inform the management of this and future pandemics elsewhere. Our data also
- highlight high inter-individual variability in anti-viral Ab responses and offer solutions for how 277
- 278 to handle this at individual and population levels.
- 279

280 Materials and methods

281

282 Human samples and ethical declaration

283 Samples from PCR+ individuals and admitted COVID-19 patients (*n*=105) were collected by 284 the attending clinicians and processed through the Departments of Medicine and Clinical Microbiology at the Karolinska University Hospital. Samples were used in accordance with 285 approval by the Swedish Ethical Review Authority (registration no. 2020-02811). All personal 286 identifiers were pseudo-anonymized, and all clinical feature data were blinded to the 287 researchers carrying out experiments until data generation was complete. PCR testing for 288 289 SARS-CoV-2 RNA was by nasopharyngeal swab or upper respiratory tract sampling at 290 Karolinska University Hospital. As viral RNA levels were determined using different qPCR 291 platforms (with the same reported sensitivity and specificity) between participants, we did 292 not analyze these alongside other features. PCR+ individuals (n=105) were questioned about 293 the date of symptom onset at their initial consultation and followed-up for serology during 294 their care, up to 2 months post-diagnosis. Serum from SARS-CoV-2 PCR+ individuals was 295 collected 6-61 days post-test, with the median time from symptom onset to PCR being 5 days. 296 In addition, longitudinal samples from 10 of these patients were collected to monitor 297 seroconversion and isotype persistence.

298

299 Hospital workers at Karolinska University Hospital were invited to test for the presence of 300 SARS-CoV-2 RNA in throat swabs in April 2020 and virus-specific IgG in serum in July 2020. We 301 screened 33 PCR+ individuals to provide additional training data for ML approaches. All 302 participants provided written informed consent. The study was approved by the National 303 Ethical Review Agency of Sweden (2020-01620) and the work was performed accordingly.

304

305 Anonymized samples from blood donors (n=100/week) and pregnant women (n=100/week) 306 were randomly selected from their respective pools by the department of Clinical 307 Microbiology, Karolinska University Hospital. No metadata, such as age or sex information 308 were available for these samples in this study. Pregnant women were sampled as part of 309 routine for infectious diseases screening during the first trimester of pregnancy. Blood donors (n=595) collected through the same channels a year previously were randomly selected for 310 311 use as negative controls. Serum samples from individuals testing PCR+ for endemic coronaviruses, 229E, HKU1, NL63, OC43 (n=20, ECV+) in the prior 2-6 months, were used as 312 313 additional negative controls. The use of study samples was approved by the Swedish Ethical Review Authority (registration no. 2020-01807). Stockholm County death and Swedish 314 315 mortality data was sourced from the ECDC and the Swedish Public Health Agency, respectively. Study samples are defined in Table 1. 316

317

318 Serum sample processing

319 Blood samples were collected by the attending clinical team and serum isolated by the 320 department of Clinical Microbiology. Samples were anonymized, barcoded and stored at -

321 20°C until use. Serum samples were not heat-inactivated for ELISA protocols but were heat-

inactivated at 56°C for 60 min for neutralization experiments. 322

323

324 SARS-CoV-2 antigen generation

The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain with a 325 C-terminal T4 fibritin trimerization motif was obtained from²⁶. The plasmid was used to 326 327 transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent (Thermo Fisher 328 Scientific). The ectodomain was purified from filtered supernatant on Streptactin XT resin (IBA 329 Lifesciences), followed by size-exclusion chromatography on a Superdex 200 in 5 mM Tris pH 330 8, 200 mM NaCl.

331

The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned upstream of a Sortase A recognition 332 333 site (LPETG) and a 6xHIS tag, and expressed in 293F cells as described above. RBD-HIS was 334 purified from filtered supernatant on His-Pur Ni-NTA resin (Thermo Fisher Scientific), followed

- 335 by size-exclusion chromatography on a Superdex 200. The nucleocapsid was purchased from
- 336 Sino Biological.
- 337

338 Anti-SARS-CoV-2 ELISA

339 96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S trimers, RBD or 340 nucleocapsid (100 μ l of 1 ng/ μ l) in PBS overnight at 4°C. Plates were washed six times with 341 PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk. Human serum samples were 342 thawed at room temperature, diluted (1:100 unless otherwise indicated), and incubated in 343 blocking buffer for 1h (with vortexing) before plating. Serum samples were incubated 344 overnight at 4°C before washing, as before. Secondary HRP-conjugated anti-human antibodies were diluted in blocking buffer and incubated with samples for 1 hour at room 345 346 temperature. Plates were washed a final time before development with TMB Stabilized Chromogen (Invitrogen). The reaction was stopped using 1M sulphuric acid and optical 347 348 density (OD) values were measured at 450 nm using an Asys Expert 96 ELISA reader (Biochrom 349 Ltd.). Secondary antibodies (all from Southern Biotech) and dilutions used: goat anti-human 350 IgG (2014-05) at 1:10,000; goat anti-human IgM (2020-05) at 1:1000; goat anti-human IgA (2050-05) at 1:6,000. All assays of the same antigen and isotype were developed for their 351 352 fixed time and samples were randomized and run together on the same day when comparing 353 binding between PCR+ individuals. Negative control samples were run alongside test samples 354 in all assays and raw data were log transformed for statistical analyses.

355

356 In vitro virus neutralisation assay

357 Pseudotyped viruses were generated by the co-transfection of HEK293T cells with plasmids 358 encoding the SARS-CoV-2 spike protein harboring an 18 amino acid truncation of the cytoplasmic tail²⁶; a plasmid encoding firefly luciferase; a lentiviral packaging plasmid 359 (Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was changed 12-16 hours post-360 361 transfection and pseudotyped viruses harvested at 48- and 72-hours, filtered through a 0.45

µm filter and stored at -80°C until use. Pseudotyped neutralisation assays were adapted from 362 protocols validated to characterize the neutralization of HIV, but with the use of HEK293T-363 ACE2 cells. Briefly, pseudotyped viruses sufficient to generate ~100,000 RLUs were incubated 364 with serial dilutions of heat-inactivated serum for 60 min at 37°C. Approximately 15,000 365 HEK293T-ACE2 cells were then added to each well and the plates incubated at 37°C for 48 366 hours. Luminescence was measured using Bright-Glo (Promega) according to the 367 368 manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration time 369 of 0.3s. The limit of detection was at a 1:45 serum dilution.

370

371 IL-6 cytometric bead array

372 Serum IL-6 levels were measured in a subset of PCR+ serum samples (n=64) using an enhanced 373 sensitivity cytometric bead array against human IL-6 from BD Biosciences (Cat # 561512). 374 Protocols were carried out according to the manufacturer's recommendations and data 375 acquired using a BD Celesta flow cytometer.

376

377 Statistical analysis of SARS-CoV-2 PCR+ data

378 All univariate comparisons were performed using non-parametric analyses (Kruskal-Wallis, 379 stratified Mann-Whitney, hypergeometric exact tests and Spearman rank correlation), as 380 indicated, while multivariate comparisons were performed using linear regression of log 381 transformed measures and Wald tests. For multivariate tests, all biochemical measures (IL-6, PSV ID50 neut., IgG, IgA, IgM) were log transformed to improve the symmetry of the 382 distribution. As "days since first symptom" and "days since PCR+ test" are highly correlated, 383 384 we cannot include both in any single analysis. Instead, we show results for one, then the other 385 (Supp. Table 1).

386

387 Probabilistic seroprevalence estimations

388 Prior to analysis, each sample OD was standardized by dividing by the mean OD of "no sample 389 controls" on that plate or other plates run on the same day. This resulted in more similar 390 distributions for 2019 blood donor samples with 2020 blood donors and pregnant volunteers, 391 as well as smaller coefficients of variation amongst PCR+ COVID patients for both SPIKE and 392 RBD.

393

394 We employed two distinct probabilistic strategies for estimating seroprevalence without 395 thresholds, each developed independently. Our machine learning approach consisted of evaluating different algorithms suited to ELISA data, which we compared through ten-fold 396 397 cross validation (CV): logistic regression (LOG), linear discriminant analysis (LDA), and support vector machines (SVM) with a linear kernel. Logistic regression and linear discriminant 398 399 analysis both model log odds of a sample being case as a linear equation with a resulting linear decision boundary. The difference between the two methods is in how the coefficients for 400 401 the linear models are estimated from the data. When applied to new data, the output of 402 logistic regression and LDA is the probability of each new sample being a case. Support vector

403 machines is an altogether different approach. We opted for a linear kernel, once again 404 resulting in a linear boundary. SVM constructs a boundary that maximally separates the 405 classes (i.e. the margin between the closest member of any class and the boundary is as wide 406 as possible), hence points lying far away from their respective class boundaries do not play 407 an important role in shaping it. SVM thus puts more weight on points closest to the class 408 boundary, which in our case is far from being clear. Linear SVM has one tuning parameter C, 409 a cost, with larger values resulting in narrower margins. We tuned C on a vector of values 410 (0.001, 0.01, 0.5, 1, 2, 5, 10) via an internal 5-fold CV with 5 repeats (with the winning parameter used for the final model for the main CV iteration). We also note that the natural 411 412 output of SVM are class labels rather than class probabilities, so the latter are obtained via 413 the method of Platt⁵⁴.

414

415 We considered three strategies for cross-validation: i) random: individuals were sampled into 416 folds at random, ii) stratified: individuals were sampled into folds at random, subject to 417 ensuring the balance of cases:controls remained fixed and iii) unbalanced: individuals were 418 sampled into folds such that each fold was deliberately skewed to under or over-represent 419 cases compared to the total sample. We sought a method that worked equally well across all 420 cross-validation schemes, as the true proportion of cases in the test data is unknown and so 421 a good method should not be overly sensitive to the proportion of cases in the training data. 422 We found most methods worked well and chose to create an ensemble (ENS) method 423 combining the method with the highest sensitivity (LOG) with the highest specificity (LDA), 424 defined as an unweighted average of the probabilities generated under both.

425

426 We trained the ensemble learner on all 733 training samples and predicted the probability of anti-SARS-CoV-2 antibodies in blood donors and pregnant volunteers sampled in 2020. The 427 428 ENS learner had average sensitivity > 99.1% and average specificity >99.8%. We inferred the 429 proportion of the sampled population with positive antibody status each week using multiple 430 imputation. We repeatedly (1,000 times) imputed antibody status for each individual 431 randomly according to the ensemble prediction, and then analyzed each of the 1,000 datasets 432 in parallel, combining inference using Rubin's rules, derived for the Wilson binomial proportion confidence interval⁵⁵. 433

434

Our Bayesian approach is explained in detail in Christian *et al*⁴⁹. Briefly, we used a logistic 435 436 regression over anti-RBD and -S training data to model the relationship between the ELISA 437 measurements and the probability that a sample is antibody-positive. We adjusted for the training data class proportions and used these adjusted probabilities to inform the 438 seroprevalence estimates for each time point. Given that the population seroprevalence 439 440 cannot increase dramatically from one week to the next, we constructed a prior over seroprevalence trajectories using a transformed Gaussian Process, and combined this with 441 442 the individual class-balance adjusted infection probabilities for each donor to infer the 443 posterior distribution over seroprevalence trajectories.

444

445 Data and code availability statement

446

447 Data generated as part of the study, along with custom code for statistical analyses, is openly 448 available repositories: https://github.com/MurrellGroup/ via our GitHub 449 DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.

450

451 **Author contributions**

452

453 GKH and XCD designed the study, analyzed the results and wrote the manuscript with input 454 from co-authors. JA, TA, JD, SM, GB, MA and SA provided the study serum samples and clinical 455 information. LH, LPV, AMM, DJS, KCI, BM and GM generated SARS-CoV-2 antigens and pseudotyped viruses. XCD and MF developed the ELISA protocols and XCD generated the 456 457 data. DJS and BM developed and performed the neutralization assay. MCh and BM developed 458 the Bayesian framework. CW and NFG assisted with patient data statistical analyses and 459 executed machine learning approaches. MA, SK, PP, MM, JC, MCo and JR carried out wet lab 460 experiments and assisted with data analysis.

461

462 Acknowledgments

463

464 We would like to thank the study participants and attending clinical teams. Secondly, we 465 extend our thanks to Björn Reinius, Marc Panas, Julian Stark, Remy M. Muts and Darío Solis 466 Sayago for their input and discussion. Funding for this work was provided by a Distinguished 467 Professor grant from the Swedish Research Council (agreement 2017-00968) and NIH (agreement 400 SUM1A44462-02). CW and NFG are funded by the Wellcome Trust 468 469 (WT107881) and MRC (MC UP 1302/5).

470

471 **Conflict of interest**

472

473 The study authors declare no competing interests related to the work.

474

475 References

- 476
- 477 1. Altman, D., Douek, D. & Boyton, R. What policy makers need to know about COVID-19 478 protective immunity. Lancet (2020) doi:https://doi.org/10.1016/S0140-479 6736(20)30985-5.
- Jonsson, S. et al. Identification of sequence variants influencing immunoglobulin 480 2. levels. Nat. Genet. (2017) doi:10.1038/ng.3897. 481
- 482 3. Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. (2020) doi:10.1038/s41591-020-0965-6. 483
- 484 4. Ibarrondo, F. J. et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild 485 Covid-19. The New England Journal of Medicine (2020) doi:10.1056/NEJMc2025179.

486	5.	Choe, P. et al. Waning antibody responses in asymptomatic and symptomatic SARS-
487		CoV-2 infection. Emerg Infect Dis 27, DOI: 10.3201/eid2701.203515 (2020).
488	6.	MacCallum, R. C., Zhang, S., Preacher, K. J. & Rucker, D. D. On the practice of
489		dichotomization of quantitative variables. Psychol. Methods (2002)
490		doi:10.1037//1082-989x.7.1.19.
491	7.	Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. <i>British</i>
492		Medical Journal (2006) doi:10.1136/bmi 332.7549.1080
192	8	Davis M M A Prescription for Human Immunology Immunity vol 29 835–838
404	0.	
494	0	(2000). Winter A.K. & Lleade C.T. The important role of corology for COVID 10 control. The
495	9.	Viniter, A. K. & Hegue, S. T. The important role of serology for COVID-19 control. The
496		Lancet Infectious Diseases (2020) doi:10.1016/S1473-3099(20)30322-4.
497	10.	Long, Q. X. <i>et al.</i> Antibody responses to SARS-CoV-2 in patients with COVID-19. <i>Nat.</i>
498		<i>Med</i> . (2020) doi:10.1038/s41591-020-0897-1.
499	11.	Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus
500		disease 2019. Clin. Infect. Dis. (2020) doi:10.1093/cid/ciaa344.
501	12.	Tan, W. et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. J Clin
502		doi: 10.11 , (2020).
503	13.	Robbiani, D. F. et al. Convergent Antibody Responses to SARS-CoV-2 Infection in
504		Convalescent Individuals. <i>Nature</i> (2020) doi:10.1101/2020.05.13.092619.
505	14.	Brouwer, P. J. M. <i>et al.</i> Potent neutralizing antibodies from COVID-19 patients define
506		multiple targets of vulnerability. <i>Science (80</i>). (2020) doi:10.1126/science.abc5902
507	15	In B et al Human neutralizing antibodies elicited by SARS-CoV-2 infection Nature
508	13.	(2020) doi:10.1038/c/1586-020-2380-7
500	16	Soudoux E at al Applysis of a SARS CoV 2 Infocted Individual Poyoals Dovelopment
509	10.	of Detent Neutralizing Antibedies with Limited Sematic Mutation. <i>Immunity</i> (2020)
510		dei:10.1016/i immuni: 2020.00.001
211	47	
512	17.	Duan, K. <i>et al.</i> Effectiveness of convalescent plasma therapy in severe COVID-19
513		patients. Proc. Natl. Acad. Sci. U. S. A. (2020) doi:10.10/3/pnas.2004168117.
514	18.	Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other
515		Human Coronaviruses. Trends in Immunology (2020) doi:10.1016/j.it.2020.03.007.
516	19.	Van Elslande, J. et al. Diagnostic performance of seven rapid IgG/IgM antibody tests
517		and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin. Microbiol. Infect. (2020)
518		doi:10.1016/j.cmi.2020.05.023.
519	20.	Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
520		Glycoprotein. <i>Cell</i> (2020) doi:10.1016/j.cell.2020.02.058.
521	21.	Cheng, M. et al. Cross-reactivity of antibody against SARS-coronavirus nucleocapsid
522		protein with IL-11. Biochem. Biophys. Res. Commun. (2005)
523		doi:10.1016/i bbrc 2005.10.088
524	22	Özcürümez M K et al SARS-CoV-2 antibody testing—questions to be asked I
525	~~.	Allergy Clin Immunol (2020) doi:10.1016/i.joci.2020.05.020
525	22	CourtsvanKossol C H at al Towards the post phase: ovaluation of corological assays
520	۷٦.	for diagnostics and exposure assessment. Net Comme dei: 10.10 (2020)
527	24	Tor diagnostics and exposure assessment. <i>Nat comms</i> doi: 10.10 , (2020).
528	24.	Deeks, J. J. et al. Antibody tests for identification of current and past infection with
529		SAKS-COV-2. Cochrane Database Syst. Rev. (2020) doi:10.1002/14651858.cd013652.
530	25.	Traugott, M. <i>et al.</i> Performance of Severe Acute Respiratory Syndrome Coronavirus 2
531		Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-
532		Linked Immunosorbent Assays and Rapid Tests. J. Infect. Dis. (2020)

533	26	
534	26.	Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion
535		conformation. Science (80). (2020) doi:10.1126/science.aax0902.
536	27.	Saraswati, K., Phanichkrivalkosil, M., Day, N. P. J. & Blacksell, S. D. The validity of
537		diagnostic cut-offs for commercial and in-house scrub typhus IgM and IgG ELISAs: A
538		review of the evidence. PLoS Negl. Trop. Dis. (2019)
539		doi:10.1371/journal.pntd.0007158.
540	28.	Xu, H., Lohr, J. & Greiner, M. The selection of ELISA cut-off points for testing antibody
541		to Newcastle disease by two-graph receiver operating characteristic (TG-ROC)
542		analysis. J. Immunol. Methods (1997) doi:10.1016/S0022-1759(97)00128-2.
543	29.	Greiner, M., Franke, C. R., Böhning, D. & Schlattmann, P. Construction of an intrinsic
544		cut-off value for the sero-epidemiological study of Trypanosoma evansi infections in a
545		canine population in Brazil: a new approach towards an unbiased estimation of
546		prevalence. <i>Acta Trop.</i> (1994) doi:10.1016/0001-706X(94)90044-2.
547	30.	Burgess, S., Ponsford, M. J. & Gill, D. Are we underestimating seroprevalence of SARS-
548		CoV-2? <i>The BMJ</i> (2020) doi:10.1136/bmj.m3364.
549	31.	Aghaeepour, N. et al. An immune clock of human pregnancy. Sci. Immunol. (2017)
550		doi:10.1126/sciimmunol.aan2946.
551	32.	Mor, G. & Cardenas, I. The Immune System in Pregnancy: A Unique Complexity.
552		American Journal of Reproductive Immunology (2010) doi:10.1111/j.1600-
553		0897.2010.00836.x.
554	33.	Kourtis, A. P., Read, J. S. & Jamieson, D. J. Pregnancy and infection. New England
555		Journal of Medicine (2014) doi:10.1056/NEJMra1213566.
556	34.	Hanke, L. <i>et al.</i> An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor
557		interaction. <i>bioRxiv</i> (2020) doi:10.1101/2020.06.02.130161.
558	35.	Herzenberg, L. A. & Herzenberg, L. A. Toward a layered immune system. <i>Cell</i> (1989)
559		doi:10.1016/0092-8674(89)90748-4.
560	36.	Cervia, C. <i>et al.</i> Systemic and mucosal antibody secretion specific to SARS-CoV-2
561		during mild versus severe COVID-19. <i>bioRxiv</i> (2020) doi:10.1101/2020.05.21.108308.
562	37.	Eto, D. <i>et al.</i> IL-21 and IL-6 are critical for different aspects of B cell immunity and
563		redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. <i>PLoS One</i>
564		6 . e17739 (2011).
565	38.	Dienz, O. <i>et al.</i> The induction of antibody production by IL-6 is indirectly mediated by
566		II-21 produced by CD4 + T cells. J. Exp. Med. (2009) doi:10.1084/iem.20081571.
567	39.	Maeda, K., Mehta, H., Drevets, D. A. & Coggeshall, K. M. IL-6 increases B-cell IgG
568		production in a feed-forward proinflammatory mechanism to skew hematopoiesis
569		and elevate myeloid production <i>Blood</i> (2010) doi:10.1182/blood-2009-07-230631
570	40	Beagley K W et al. Interleukins and IgA synthesis. Human and murine interleukin 6
571	40.	induce high rate IgA secretion in IgA-committed B cells 1 Exp. Med. (1989)
572		doi:10.1084/jem.169.6.2133
572	/11	Mayer 1 et al. Signaling by II-6 promotes alternative activation of macrophages to
575	41.	limit ondotoxomia and obosity associated resistance to inculin. Nat. Immunol. (2014)
574		doi:10.1028/pi.2965
575	10	Wistianson O. D. & Mandrun Doulson T. Interlaukin 6 and dishetes. The good the
570	42.	had or the indifferent? Diabates (200E) doi:10.2227/diabates E4 suppl. 2.5114
5// 570	10	Dau, or the mainterent? <i>Diabetes</i> (2005) doi:10.2337/diabetes.54.suppi_2.5114.
5/8 570	43.	Ferreira, K. C. <i>et ul.</i> Functional ILOK 358AIA Allele Impairs Classical IL-6 Receptor
5/9		Signaling and influences Risk of Diverse Inflammatory Diseases. PLoS Genet. 9, (2013).

medRxiv preprint doi: https://doi.org/10.1101/2020.07.17.20155937; this version posted October 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

porpotate	· ·
It is made available under a CC-B	Y 4.0 International license .

580 581 582	44.	Park, W. Y. <i>et al.</i> Cytokine balance in the lungs of patients with acute respiratory distress syndrome. <i>Am. J. Respir. Crit. Care Med.</i> (2001) doi:10.1164/airccm.164.10.2104013.
583 584 585	45.	Magro, G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc. <i>Cytokine: X</i> (2020) doi:10.1016/j.cytox.2020.100029.
586 587 588	46.	Chua, R. L. <i>et al.</i> COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. <i>Nat. Biotechnol.</i> (2020) doi:10.1038/s41587-020-0602-4.
589 590	47.	<i>et al.</i> Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. <i>Science (80).</i> (2020) doi:10.1126/science.abd4250.
591 592 593	48.	Bartosch, B. <i>et al.</i> In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes. <i>Proc. Natl. Acad. Sci. U. S. A.</i> (2003) doi:10.1073/pnas.2335981100.
594 595	49.	Christian, M. & Murrell, B. Discriminative Bayesian Serology: Counting Without Cutoffs. <i>BioRxiv</i> (2020).
596 597 598	50.	Larios Mora, A. <i>et al.</i> Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. <i>MAbs</i> (2018)
599 600	51.	Sheridan, C. Ablynx's nanobody fragments go places antibodies cannot. <i>Nat.</i> <i>Biotechnol.</i> (2017) doi:10.1038/nbt1217-1115.
601 602	52.	Intensivvårdsregistret, S. Antal som intensivvårdas med Covid-19 per dag. Svenska Intensivvårdsregistrets utdataportal
603 604 605	53.	https://portal.icuregswe.org/siri/report/corona.co (2020). Paterlini, M. 'Closing borders is ridiculous': the epidemiologist behind Sweden's controversial coronavirus strategy. <i>Nature</i> (2020) doi:10.1038/d41586-020-01098-x.
606 607	54.	Platt, J. & others. Probabilistic outputs for support vector machines and comparisons to regularized likelihood methods. <i>Adv. large margin Classif.</i> (1999).
608 609 610 611	55.	Lott, A. & Reiter, J. P. Wilson Confidence Intervals for Binomial Proportions With Multiple Imputation for Missing Data. <i>Am. Stat.</i> (2020) doi:10.1080/00031305.2018.1473796.
612		



Figure 1: Anti-SARS-CoV-2 Ab phenotypes in COVID-19 patients, PCR+ individuals, blood donors and pregnant women (A) Raw optical density (OD) anti-S and -RBD IgG responses are shown in SARS-CoV-2 PCR+ individuals (n=105), blood donors (BD, n=1,500) and pregnant women (PW, n=1,400). Controls, C, represent n=595 blood donors from spring 2019. Conventional 6 SD cut-offs shown by dotted lines. (B) IgM, IgG and IgA responses against S and RBD in PCR+ individuals (n=105), with a limited number of controls for each assay represented by open circles. (C) Anti-viral Ab levels are associated with disease severity, most pronounced for IgA. COVID-19 patients in the ICU category were mechanically ventilated. Anti-S and RBD responses are graphed together. (D) Two discordant longitudinal profiles of seroconversion and neutralisation capacity are shown. (E) *In vitro* pseudotyped virus neutralization ID₅₀ titers are associated with disease severity, with the highest titers observed in Cat 3 (ICU) patients. Forty-eight SARS-CoV-2 PCR+ individuals analyzed in duplicate. (F) Comparison of neutralization ID₅₀ titers between PCR+ individuals (n=48), BD (n=28) and PW (n=28), all analyzed in duplicate. Bars represent the geometric mean and *P* values are from a two-tailed Mann-Whitney test.



Figure 2: Probability-based seroprevalence estimates in Stockholm during the initial outbreak

(A) Study sample collection intervals are shown alongside the 14-day COVID-19 death rate per million inhabitants in Sweden and relevant countries for comparison. (B) Log-transformed un-normalized OD measurements from all BD and PW in the study. Conventional 3 (dotted red line) and 6 SD (solid red line) cut-offs are shown; calculated from *n*=595 historical controls; 100 random negative controls (C, with 95% CI of the median) are shown for each assay. (C) The percentage anti-S and -RBD IgG positive per sampling week in BD and PW show according to 3 or 6 SD cut-offs. (D) S and RBD responses from PCR+ individuals were used to train different machine learning algorithms to assign likelihood of past infection. We created an ensemble learner (*ENS*) from the output of logistic regression and linear discriminant analysis, providing a highly sensitive, specific and consistent multi-dimensional solution to the problem of weak reactors, and assigning each data point a probability of being positive. Conventional 3 and 6 SD cut-offs are shown for each antigen, with probabilities assigned to selected points. (E) Heatmap of assigned *ENS* probabilities for the top 35 BD and PW values per week, with each square representing an individual. (F) Seroprevalence (SP) estimates in Stockholm modelled over time in BD and PW using a cut-off-independent Bayesian framework.

Table 1 – Study samples

SARS-CoV-2 PCR+ in	<u>dividuals[§]</u>	<i>n=</i> 105			
Females		<i>n=</i> 44 (41.9%)			
Males		<i>n=</i> 61 (58.1%)			
Median age (years)		53.0 (49-61)			
	Females	51.5 (48-56.2)			
	Males	55.0 (49-63)			
Non-hospitalized		<i>n=</i> 53			
	Females, males	28, 25			
Hospitalized patients		<i>n=</i> 31			
	Females, males	12, 17			
Intensive care (ICU) pa	itients	<i>n=</i> 21			
	Females, males	3, 17			
SARS-CoV2+ PCR		<i>n=</i> 105			
Sample collection date	S	March-August 2020			
SARS-CoV-2 PCR+ K	<u>hospital staff</u>	<i>n=</i> 33			
Sample collection date	s	July 2020			
D 1 1 1		4 500			
Blood donors		<i>n</i> =1,500			
Sample collection date	S	Weeks 14-34 (March-August) 2020			
Pregnant women		<i>n=</i> 1,400			
Sample collection date	S	Weeks 17-34 (April-August) 2020			
Historical blood dong	ors	<i>n=</i> 595			
Sample collection date	S	April-June 2019			
ECV+ donors		<i>n=</i> 20			
Sample collection date	S	July-December 2019			
[§] Under the care of Karolinska University Hospital No additional metadata available for any samples					



Figure S1: Anti-SARS-CoV-2 ELISA protocol development

(A) Trimeric S and RBD were expressed in 293F cells and purified as described. (B) A random subset of PCR+ individuals, negative controls and BD were used to validate the assays for the three isotypes, these were individuals with confirmed SARS CoV-2 infection (n=36, from a range of disease severity categories); blood donors from the spring of 2020 (n=100); two sets of negative controls, blood donors from the spring of 2019 (n=75) and individuals PCR+ for endemic coronaviruses (ECV+) (n=20). (C) Two ECV+ donors, K2 and K4, showed reproducible IgM binding to S. Testing of another subset of historical controls (n=75) for a similar observation, two additional individuals were found to show IgM binding to S. (D) Serial dilutions of PCR+ participant serum are shown (in a representative sample, n=40) of titrated individuals for anti-S and anti-RBD IgG.





(A) Log10 OD450 anti-S and -RBD IgG responses in SARS-CoV-2 PCR+ individuals and healthy donors, with a 6 SD cut-off shown calculated from all 595 negative control values. (B) Raw OD450 isotypic responses in PCR+ individuals. A limited number of negative controls are depicted by clear circles. (C) Anti-S vs -RBD responses in PCR+ individuals are highly correlated. (D) Elevated anti-viral Ab and serum IL-6 are associated with disease severity in PCR+ individuals, IgM and IgG.





(A) Antibody responses according to sex for anti-S and –RBD IgA. (B) IgM and IgA titers declined with time from first symptom/SARS-CoV-2+ PCR. IgG levels were maintained during this time. *P* values from a Spearman rank correlation test. (C) Spearman's rank correlation of PCR+ dataset features and antibody levels. DOB - *date of birth*; d-p SymO - *days post-symptom onset*; d-p PCR – *days post SARS-CoV-2+ PCR*; PSV ID50 – *neutralizing titer* (D) Adjusted fold-change for dataset features in PCR+ individuals compared to category 1. The effects of age (DOB), sex, days from PCR test were considered.



Figure S4: Considerations and methods for SP estimates in BD and PW

(A) Random sub-sampling of non-overlapping negative controls illustrates how the range of negative control values can influence the conventional test cut-off. Depending on the control values used to set the test threshold for positivity, seroprevalence (SP) estimates vary by 40%. 600 BD and PW values are used as an example. Anti-S IgG values are shown. (B) The distribution of negative control serum values for anti-S and –RBD IgG. (C) As ML methods improve with additional data, we analyzed a small cohort (n=33) of PCR+ Karolinska University hospital staff (HS) for S and RBD IgG responses. n=32 historical controls, C, were analyzed alongside. (D) Comparison of logistic regression, linear discriminant analysis and the *ENS* learner, showing the training data set and BD and PW test samples. *ENS* was trained using 595 negative control values and 138 PCR+ individuals. (E) *ENS* identified several study BD and PW to have uncertain measurements when S and RBD responses were considered, facilitating individual re-testing.

Supplementary Table 1

COVID-19 patient multivariate analysis

Days from first symptom

Days from SARS-CoV-2+ PCR test

IL.6					IL.6				
	Estimate	Std. Error	t value	Pr(>ltl)		Estimate	Std. Error	t value	Pr(>ltl)
(Intercept)	1.0808524	0.7558497	1.4299833	0.1589412	(Intercept)	1.3337536	0.7900611	1.6881651	0.0972562
Days.FFS	-0.0138028	0.0092132	-1.4981536	0.1403806	Days.PCR	-0.0179820	0.0091674	-1.9615105	0.0550817
Severity2	0.6751029	0.2725780	2.4767330	0.0166860	Severity2	0.5419503	0.2784989	1.9459695	0.0569693
Severity3	2.0818073	0.3139723	6.6305441	0.0000000	Severity3	1.7879936	0.3174311	5.6326988	0.000007
SexF	-0.0048214	0.2490798	-0.0193569	0.9846335	SexF	-0.0418102	0.2496296	-0.1674892	0.8676226
Years	0.0006194	0.0120141	0.0515519	0.9590912	Years	-0.0002995	0.0127464	-0.0234942	0.9813443
ness with 2	outliers remo	oved		chec	cking robustness with 2	outliers remo	oved		
	Estimate	Std. Error	t value	Pr(>ltl)		Estimate	Std. Error	t value	Pr(>ltl)
(Intercept)	0.5938320	0.6085196	0.9758633	0.3340249	(Intercept)	0.7050756	0.6754753	1.0438215	0.3014906
Days.FFS	-0.0048689	0.0073761	-0.6600921	0.5123499	Days.PCR	-0.0046541	0.0079825	-0.5830368	0.5624379
Severity2	0.6314650	0.2134847	2.9578929	0.0047955	Severity2	0.5212971	0.2297047	2.2694227	0.0275018
Severity3	1.5427576	0.2627737	5.8710497	0.0000004	Severity3	1.3678120	0.2739547	4.9928394	0.000073
SexF	-0.1881632	0.2020666	-0.9311939	0.3564134	SexF	-0.1798193	0.2123891	-0.8466500	0.4011457
Years	0.0047880	0.0095726	0.5001784	0.6192350	Years	0.0039051	0.0107259	0.3640784	0.7173046
PSV.ID50					PSV.ID50				
	Estimate	Std. Error	t value	Pr(>ltl)		Estimate	Std. Error	t value	Pr(>ltl)
(Intercept)	4.5012562	1.8338893	2.4544864	0.0193831	(Intercept)	5.2752610	1.6958032	3.1107742	0.0035845
Days.FFS	-0.0150209	0.0222419	-0.6753408	0.5040267	Days.PCR	-0.0282459	0.0190912	-1.4795302	0.1474633
Severity2	1.4888195	0.5062151	2.9410804	0.0058489	Severity2	1.4647193	0.4544978	3.2227205	0.0026504
Severity3	1.4175205	1.0591033	1.3384157	0.1896430	Severity3	1.9419796	0.7912711	2.4542533	0.0189450
SexF	-0.1325308	0.4944022	-0.2680627	0.7902707	SexF	0.1871493	0.4244939	0.4408763	0.6618680
Years	0.0484696	0.0266019	1.8220360	0.0772562	Years	0.0378735	0.0253337	1.4949856	0.1433991
tness with 1	outlier remo	oved		che	cking robustness with 1	outlier remo	ved		
	Estimate	Std. Error	t value	Pr(>ltl)		Estimate	Std. Error	t value	Pr(>ltl)
(Intercept)	4.5186312	1.7467553	2.5868713	0.0142822	(Intercept)	5.3454881	1.5958448	3.3496292	0.0019089

Days.FFS-0.00635060.0215775-0.29431310.7703621Severity21.21951310.49867242.44551960.0199661Severity31.44344291.00884521.43078730.1618932SexF-0.00044800.4750254-0.00094310.9992532Years0.04038110.02562441.57588580.1245916

Estimate Std. Error t value

(Intercept) -0.4338183 0.1572226 -2.7592622 0.0070039 Days.FFS 0.0056162 0.0018643 3.0124437 0.0033555

Severity2 0.2636915 0.0582979 4.5231746 0.0000183

Severity3 0.1553421 0.0760363 2.0429981 0.0439450

Estimate Std. Error t value

(Intercept) -0.5916830 0.2306770 -2.5649851 0.0119546

Days.FFS 0.0034375 0.0027353 1.2566928 0.2120811

Severity2 0.3166891 0.0855347 3.7024646 0.0003657 Severity3 0.3183027 0.1115605 2.8531842 0.0053580

-0.1061612 0.0537241 -1.9760431 0.0511786

0.0025710 0.0026281 0.9782727 0.3305330

-0.1630434 0.0788241 -2.0684471 0.0414354

0.0021569 0.0038560 0.5593721 0.5772819

S.IqG

SexF

Years

RBD.lgG

SexF Years Days.PCR-0.01973760.0183073-1.07812550.2881490Severity21.21062160.44047212.74846390.0092996Severity31.99069950.74478052.67286730.0112300SexF0.30623240.40245770.76090590.4516688Years0.02979670.02407151.23784180.2237872

S.lgG

Pr(>ltl)

Pr(>ltl)

EstimateStd. Errort valuePr(>ltl)(Intercept)-0.39437620.1612688-2.44545890.0163490Days.PCR0.00559960.00193572.89280240.0047551Severity20.27369180.06001354.56050060.0000155Severity30.19241810.07649242.51551920.0136010SexF-0.07616600.0536223-1.42041810.1588299Years0.00212110.00272620.77801240.4385365

RBD.lgG

EstimateStd. Errort valuePr(>ltl)(Intercept)-0.48641430.2323367-2.09357460.0390193Days.PCR0.00262590.00278870.94163320.3488201Severity20.30908810.08646033.57491310.0005579Severity30.34120880.11020113.09623910.0025904SexF-0.13734440.0772525-1.77786320.0786949Years0.00098670.00392770.25121890.8021991

S.IgMEstimateStd. Errort valuePr(>Itl)(Intercept)-0.83006280.3562796-2.32980740.0220285Days.FFS-0.01176700.0042247-2.78529430.0065067Severity20.42168300.13210793.19195880.0019404Severity30.12564750.17230470.72921680.4677418SexF-0.16039180.1217434-1.31745760.1909928Years0.01443080.00595562.42306960.0173698

S.IgM

EstimateStd. Errort valuePr(>Itl)(Intercept)-0.70234420.3495024-2.00955500.0473764Days.PCR-0.01405270.0041950-3.34985890.0011693Severity20.39450680.13006163.03323130.0031359Severity30.14802180.16577460.89290990.3742101SexF-0.05471740.1162104-0.47084810.6388518Years0.01139590.00590831.92877690.0568080

RBD.lgM					RBD.lgM				
	Estimate	Std. Error	t value	Pr(>ltl)		Estimate	Std. Error	t value	Pr(>ltl)
(Intercept)	-1.0387929	0.4130592	-2.5148767	0.0136629	(Intercept)	-0.8655000	0.3973594	-2.178129	0.0319255
Days.FFS	-0.0138623	0.0048980	-2.8302083	0.0057240	Days.PCR	-0.0172033	0.0047694	-3.606981	0.0005008
Severity2	0.5057259	0.1531617	3.3019087	0.0013732	Severity2	0.4913299	0.1478708	3.322698	0.0012758
Severity3	0.1944795	0.1997646	0.9735434	0.3328641	Severity3	0.2406897	0.1884739	1.277045	0.2047656
SexF	-0.2399048	0.1411454	-1.6996999	0.0926033	SexF	-0.1394645	0.1321230	-1.055566	0.2939009
Years	0.0171226	0.0069047	2.4798392	0.0149844	Years	0.0133309	0.0067174	1.984546	0.0501421
S.lgA					S.lgA				
	Estimate	Std. Error	t value	Pr(>ltl)		Estimate	Std. Error	t value	Pr(>ltl)
(Intercept)	-0.2343625	0.3626807	-0.6461952	0.5197793	(Intercept)	-0.3012762	0.3728826	-0.8079654	0.4211724
Days.FFS	-0.0097902	0.0043006	-2.2764744	0.0251627	Days.PCR	-0.0098957	0.0044757	-2.2110117	0.0294865
Severity2	0.7529383	0.1344814	5.5988283	0.000002	Severity2	0.6714710	0.1387621	4.8390072	0.0000052
Severity3	1.0042292	0.1754004	5.7253524	0.000001	Severity3	0.9000684	0.1768642	5.0890358	0.0000019
SexF	-0.2661040	0.1239307	-2.1472001	0.0344358	SexF	-0.2758111	0.1239844	-2.2245634	0.0285297
Years	-0.0057710	0.0060626	-0.9519015	0.3436685	Years	-0.0041292	0.0063036	-0.6550579	0.5140475
RBD.lgA					RBD.lgA				
	Estimate	Std. Error	t value	Pr(>ltl)		Estimate	Std. Error	t value	Pr(>ltl)
(Intercept)	-0.2710503	0.4094717	-0.6619513	0.5096753	(Intercept)	-0.2267285	0.4122576	-0.5499679	0.5836598
Days.FFS	-0.0180531	0.0048554	-3.7181129	0.0003466	Days.PCR	-0.0196414	0.0049483	-3.9693438	0.0001418
Severity2	0.5614106	0.1518315	3.6975911	0.0003718	Severity2	0.4589973	0.1534149	2.9918687	0.0035499
Severity3	0.9648132	0.1980296	4.8720661	0.0000046	Severity3	0.8788819	0.1955404	4.4946297	0.0000200
SexF	-0.4683261	0.1399195	-3.3471098	0.0011886	SexF	-0.4433399	0.1370767	-3.2342474	0.0016890
Years	-0.0023814	0.0068447	-0.3479188	0.7287046	Years	-0.0029664	0.0069692	-0.4256455	0.6713496

Supplementary Table 2

ENS learner estimates

Туре	Week	Ν	Estimate	lower.ci	upper.ci
Blood donors	Wk14	100	0.0105199999999998	0.00186267413688987	0.0571124452130694
Blood donors	Wk17	100	0.059930000000007	0.0277067084436435	0.124818422697639
Blood donors	Wk18	100	0.030250000000004	0.0103369986968445	0.0852198537817097
Blood donors	Wk19	100	0.0819899999999993	0.0420758061055538	0.153692847546347
Blood donors	Wk20	100	0.088830000000009	0.046518592804669	0.163045245940735
Blood donors	Wk21	100	0.060620000000007	0.0279295559709151	0.126590435953148
Blood donors	Wk22	100	0.0518599999999995	0.0223967600811795	0.115503146139443
Blood donors	Wk23	100	0.1031399999999999	0.0568755500979782	0.179860591957947
Blood donors	Wk24	100	0.0491799999999993	0.0208070659558649	0.111824427597925
Blood donors	Wk25	100	0.064590000000004	0.0299472449446712	0.133780545972474
Blood donors	Wk30	100	0.14169	0.0843021051364242	0.22839998832092
Blood donors	Wk31	100	0.08807000000001	0.0460906749148218	0.161798798516266
Blood donors	Wk32	100	0.13474	0.07991254449231	0.218260850763384
Blood donors	Wk33	100	0.12209000000001	0.0711556354845674	0.201571777003771
Blood donors	Wk34	100	0.18131000000001	0.116915378458736	0.270315226797433
Pregnant volunteers	Wk17	100	0.02785	0.00854309329510716	0.0869623409679927
Pregnant volunteers	Wk18	100	0.059310000000001	0.0263543448650153	0.128056041293278
Pregnant volunteers	Wk19	100	0.0779199999999988	0.0392832595316614	0.148676738526427
Pregnant volunteers	Wk20	100	0.061350000000007	0.028401055595685	0.12750757406586
Pregnant volunteers	Wk21	100	0.09044000000002	0.0482644667169825	0.163152425697498
Pregnant volunteers	Wk22	100	0.0205599999999997	0.00565556676979313	0.0719026340509295
Pregnant volunteers	Wk23	100	0.0725799999999993	0.0355650368403294	0.142429663079253
Pregnant volunteers	Wk24	100	0.090210000000021	0.0481585199364663	0.162703789795822
Pregnant volunteers	Wk25	100	0.0705999999999996	0.0338472442954616	0.141419016311214
Pregnant volunteers	Wk30	100	0.13676	0.0802505417653763	0.22339634766703
Pregnant volunteers	Wk31	100	0.10084	0.0549469530519067	0.17785049838699
Pregnant volunteers	Wk32	100	0.1025	0.055496584850798	0.181656768852696
Pregnant volunteers	Wk33	100	0.09887999999999996	0.0537530085744113	0.174890088243812
Pregnant volunteers	Wk34	100	0.092120000000004	0.0482559484435156	0.168784935290148

7591523687 534433189
634433189
20200255
768380322
433120669
399484158
8989258544
182613079
10633583
523482377
506826778
990235433
192324389
527188935
997104021

Supplementary Table 3

Bayesian framework esimates

Weeks low_95 Cl	low_70 Cl	median	high_70 Cl	high_95 Cl
14 0.00360153207381020	09 0.010015687500615324	0.02436939594002145	0.043456945152414495	0.05616568875771716
15 0.01330985792711748	0.020660967591371423	0.032365176467805026	0.04686039254667125	0.057377820643647284
16 0.02043808572781734	0.029802245381973035	0.040635466265145775	0.05175183854151783	0.060108358798232966
17 0.02876991849448829	06 0.03854036071416008	0.0474550179123166	0.056517830868095725	0.06401279669503077
18 0.0378353742021553	4 0.04509305165735621	0.052891120720793466	0.061614679337302775	0.06926247627139652
19 0.0454621750433074	5 0.050609840723507125	0.05808259302264415	0.0667054486902604	0.07438983764874765
20 0.0498930261618500	0.054706576021972896	0.06245970619115278	0.07129624957262747	0.07830821520536643
21 0.0521467423382186	0.05791442812480507	0.06609758175045291	0.07540895724676397	0.08350881740670542
22 0.05504782731919543	5 0.06082934394956948	0.06969771188215743	0.07893154646022037	0.08722346458242437
23 0.0571176803256864	0.0637732596810297	0.07335796512117096	0.08312494379587673	0.09144734645121028
24 0.06014606597769269	0.06715508580434398	0.07787976883612677	0.08778705973980627	0.09682553258559098
25 0.06299793120194423	0.07069250124677944	0.0826946388601972	0.09317717560756934	0.10369128433164672
26 0.06602989547112409	0.07508000767946306	0.08853855012377168	0.09994937727503311	0.11182458833601834
27 0.0698590882157652	0.08017185227745025	0.0943598228711556	0.10855805993002561	0.11926306095722854
28 0.07476922509955214	0.08558359989814068	0.10022639992693635	0.11541477895810452	0.1271732638528928
29 0.08082697654221173	0.09275025575500671	0.10674528554019073	0.1217751009883986	0.1344831422782898
30 0.08646878995507364	0.09813325123006669	0.11267222418259133	0.12725420939287801	0.13926953632738423
31 0.09151610720807343	0.10385128682754727	0.11794062384310447	0.13236742750330485	0.14463687104722203
32 0.0964447107286301	0.10818117279519804	0.12286691608479247	0.1371665138984982	0.1507955221582018
33 0.09949317715060758	0.11140308251196819	0.12768748654593065	0.14278530800957942	0.15741777628373163
34 0.1011389937861535	0.11440405570419197	0.1318447325503226	0.14907986575631751	0.16784211995757845

S